ArticleOrphanet journal of rare diseases2025
Danon disease in male patients: a prospective natural history study to augment understanding of the phenotype.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundDanon disease (DD) is a rare X-linked cardioskeletal myopathy caused by pathogenic mutations in lysosomal-associated membrane protein-2 (LAMP2). It is a multisystemic disease that affects the heart, skeletal, neurologic and ophthalmic systems. With an early age of onset especially in males and no treatment for the cardiomyopathy outside of heart transplant, natural history studies have been paramount to providing clinical data for the development and advancement of disease-focused therapies. Herein we present a comprehensive, prospective study detailing both cardiac and extracardiac features of DD.
methodsThe cohort was comprised of 8 male pediatric and 1 male young adult patient, enrolled at the University of California, San Diego. Diagnosis of DD was confirmed with a pathogenic or likely pathogenic LAMP2 variants. The patients underwent serial quality of life, neuropsychological, cognitive, ophthalmological, cardiac, pulmonary, and neuromuscular assessments every 6 months for 3 years.
resultsThe mean age of the cohort at study enrollment was 11.6 ± 4.5 years. The mean age of the cohort at diagnosis was 6.5 ± 5.2 years. Quality of life: assessed through the Pediatric Cardiac Quality of Life Inventory (PCQLI) and Pediatric Quality of Life Inventory (PQLQ) reveals perceptions of poor quality of life by both patients and parents. Cognitive: Differential Ability Scales-II (DAS-II) and Vineland Adaptive Behavior Scales-3 (VABS-3) showed marked intellectual disability at baseline. Cardiac: over time, ejection fraction decreased, myocardial walls thickened, and left ventricular mass increased. Pulmonary: FVC increased over time; cardiopulmonary exercise testing (CPET) revealed decreased exercise capacity as measured by peak oxygen uptake (peak VO2 max) and 6-minute walk test (6MWT). Neuromuscular: most patients in the cohort achieved maximum scores on North Star Ambulatory Assessment (NSAA), with minimal changes over 6-month follow-up; they were faster than a study of normal children during the 10-meter walk test (10MWT); they were slower than a study of normal children during time to rise and the 4-stair climb test.
conclusionNatural history studies provide an important opportunity to study rare diseases, especially when longitudinal data is available to characterize clinical changes and disease course. In the case of DD, young, male patients were found to have general deficits across quality-of-life indices and cognitive, cardiac, neuromuscular, ophthalmologic, and pulmonary functions. Stabilization or improvements in these domains may be appropriate outcomes for clinical trials to consider.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.